HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
1 published article · Updated continuously
9 trials tracked for Hepatocellular carcinoma (HCC): 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 275 citations.
Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Tislelizumab has demonstrated statistically significant improvements in both Overall Survival (OS) and Objective Response Rate (ORR) for patients with hepatocellular carcinoma. In a Phase 3 trial, Tislelizumab showed an OS of 15.9 months compared to 14.1 months (p=0.0398) and a BIRC-assessed ORR of 14.3% compared to 5.4% (p=0.0003) 1. A separate Phase 2 trial also confirmed a significant ORR of 12.9% (p=0.0001) with Tislelizumab 6.
Other established treatments for hepatocellular carcinoma include Lenvatinib 2 and Pexastimogene Devacirepvec (Pexa Vec) 3.
AI synthesis of 5 cited trials, updated Oct 1, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.